Gilead Sciences Inc

Latest stories

6h
Boston Globe
Joe Kennedy III owns stock in expensive Hep C drugUS Representative Joseph Kennedy III has earned stock value of up to $434,999 f
Joe Kennedy III owns stock in expensive Hep C drug
Boston Globe / Posted 6 hours ago
US Representative Joseph Kennedy III has earned stock value of up to $434,999 from investments in Gilead Sciences, Inc., the manufacturer of a controversially priced hepatitis C drug, Sovaldi, that many of Kennedy’s constituents are struggling to... Read more
14h
Market Watch
Merck revenue hit by generic competition, dollarfor hepatitis C, the latest entrant in a booming market for drugs for the viral
Merck revenue hit by generic competition, dollar
Market Watch / Posted 14 hours ago
for hepatitis C, the latest entrant in a booming market for drugs for the viral infection -- a market now dominated by Gilead Sciences Inc. Merck had initial sales of $50 million for Zepatier in the first quarter. The company posted a profit... Read more
7 related stories
19h
Daily Mail
Hepatitis C now kills more Americans than 60 other infectious diseasescancer, liver disease, inflammation of the liver, and other hep C-related disea
Hepatitis C now kills more Americans than 60 other infectious diseases
Daily Mail / Posted 19 hours ago
cancer, liver disease, inflammation of the liver, and other hep C-related diseases. Darryl Kato, research scientist for Gilead Sciences Inc., works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster... Read more
28 related stories
3d
FOX Business
Good News: Gilead Sciences Discounted Its Drugs AgainImage source: Gilead Sciences, inc. Gilead Sciences reported its Q1 2016 earn
Good News: Gilead Sciences Discounted Its Drugs Again
FOX Business / Posted 3 days ago
Image source: Gilead Sciences, inc. Gilead Sciences reported its Q1 2016 earnings on April 29, and on the surface things looked pretty ugly for the hepatitis C treatment leader. Gilead missed analyst estimates on both revenue and earnings, and HCV... Read more
7 related stories
3d
FOX Business
Good News: Gilead Sciences Discounted Its Drugs AgainImage source: Gilead Sciences, inc. Continue Reading Below Gilead Sciences r
Good News: Gilead Sciences Discounted Its Drugs Again
FOX Business / Posted 3 days ago
Image source: Gilead Sciences, inc. Continue Reading Below Gilead Sciences reported its Q1 2016 earnings on April 29, and on the surface things looked pretty ugly for the hepatitis C treatment leader. Gilead missed analyst estimates on both... Read more
7 related stories
3d
TheStreet.com
Don't give up on gilead following a weak q1at least, according to Porges. Gilead and Merck reportedly have until today to
Don't give up on gilead following a weak q1
TheStreet.com / Posted 3 days ago
at least, according to Porges. Gilead and Merck reportedly have until today to file additional arguments. The case is Gilead Sciences Inc. v. Merck & Co., 13-cv-04057, U.S. District Court, Northern District of California (San Jose). Beyond... Read more
3d
Investopedia
Gilead Stock Punished on Q1 Earnings Miss (GILD)Is it time to exit Gilead Sciences Inc. (GILD) or has a buying opportunity been
Gilead Stock Punished on Q1 Earnings Miss (GILD)
Investopedia / Posted 3 days ago
Is it time to exit Gilead Sciences Inc. (GILD) or has a buying opportunity been created? That's the question investors must reconcile after watching shares of the biopharmaceutical company plunge almost 10% on Friday on heavy trading volume following... Read more
7 related stories
4d
Investopedia
The 3 Largest Alpha-Seeking ETFs (PKW, PDP)in the portfolio is Apple Inc. (NASDAQ: AAPL) at 2.99%, followed by The Priceli
The 3 Largest Alpha-Seeking ETFs (PKW, PDP)
Investopedia / Posted 4 days ago
in the portfolio is Apple Inc. (NASDAQ: AAPL) at 2.99%, followed by The Priceline Group Inc. (NASDAQ: PCLN) with 2.83% and Gilead Sciences Inc. (NASDAQ: GILD) at 2.67%. With AUM of $1.43 billion and average daily volume of $15.79 million, as of... Read more
8 related stories
5d
The Auto Channel
Young Scientists from Around the State Will Compete For Top Honors at the 65th California State Science FairSouthern California Gas Company, THE MUSES of the California Science Center Fou
Young Scientists from Around the State Will Compete For Top Honors at the 65th California State Science Fair
The Auto Channel / Posted 5 days ago
Southern California Gas Company, THE MUSES of the California Science Center Foundation, The Ralph M. Parsons Foundation and Gilead Sciences, Inc. Robert Curbeam, vice president of Mission Assurance,� Quality and Raytheon Six Sigma™ for Raytheon... Read more
6d
Daily Herald
Molina Healthcare and Seagate skid, Amazon surgesdeals site's first-quarter results met expectations, but investors remained con
Molina Healthcare and Seagate skid, Amazon surges
Daily Herald / Posted 6 days ago
deals site's first-quarter results met expectations, but investors remained concerned about the health of its business. Gilead Sciences Inc., down $8.79 to $88.21 The biotech drugmaker's results were hurt by big discounts and rebates on its... Read more
6d
Investopedia
Gilead Stock: Analyzing 5 Key Suppliers (GILD)Gilead Sciences Inc. (NASDAQ: GILD) is a medical research and biopharmaceutical
Gilead Stock: Analyzing 5 Key Suppliers (GILD)
Investopedia / Posted 6 days ago
Gilead Sciences Inc. (NASDAQ: GILD) is a medical research and biopharmaceutical firm based in California. It develops and markets medicines targeting a wide variety of life-threatening illnesses, including cardiovascular disease, HIV/AIDS,... Read more
6d
FOX Business
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weighdespite those gainers, the overall mood remained sour, hurt by weak reports fro
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weigh
FOX Business / Posted 6 days ago
despite those gainers, the overall mood remained sour, hurt by weak reports from Twitter Inc.(TWTR) and Gilead Sciences Inc.(GILD) released earlier in the week. Baidu.com Inc. (BIDU) shares soared after profit fell, but revenue... Read more
11 related stories
6d
FOX Business
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weighdespite those gainers, the overall mood remained sour, hurt by weak reports fro
Stocks Struggle To Hold Monthly Gains As Earnings, Data Weigh
FOX Business / Posted 6 days ago
despite those gainers, the overall mood remained sour, hurt by weak reports from Twitter Inc.(TWTR) and Gilead Sciences Inc.(GILD) released earlier in the week. Baidu.com Inc. (BIDU) shares soared after profit fell, but revenue... Read more
11 related stories
7d
FOX Business
9 Figures That Sum Up Gilead Sciences' First QuarterImage source: Gilead Sciences, Inc. After reporting first-quarter financials t
9 Figures That Sum Up Gilead Sciences' First Quarter
FOX Business / Posted 7 days ago
Image source: Gilead Sciences, Inc. After reporting first-quarter financials that were shy of industry watchers' forecast, Gilead Sciencesshares were trading down 5% after the bell today. Investors wondering if Gilead Sciences shares are a buy or... Read more
13 related stories
7d
FOX Business
9 Figures That Sum Up Gilead Sciences' First QuarterImage source: Gilead Sciences, Inc. Continue Reading Below After reporting fi
9 Figures That Sum Up Gilead Sciences' First Quarter
FOX Business / Posted 7 days ago
Image source: Gilead Sciences, Inc. Continue Reading Below After reporting first-quarter financials that were shy of industry watchers' forecast, Gilead Sciencesshares were trading down 5% after the bell today. Investors wondering if Gilead... Read more
13 related stories
7d
The Tampa Tribune
Gilead 1Q profit tumbles on slower hepatitis C drug salesforecast of Wall Street analysts who were looking for earnings of $3.12 per sha
Gilead 1Q profit tumbles on slower hepatitis C drug sales
The Tampa Tribune / Posted 7 days ago
forecast of Wall Street analysts who were looking for earnings of $3.12 per share, according to Zacks Investment research. Gilead Sciences Inc., based in Foster City, California, has grown into one of the world's biggest drugmakers thanks to its... Read more
13 related stories
7d
Market Watch
Gilead reports drop in hepatitis C drug revenueGilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the f
Gilead reports drop in hepatitis C drug revenue
Market Watch / Posted 7 days ago
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations, suggesting competition is eating into the company's hold on a hot corner of the drug... Read more
13 related stories
7d
FOX Business
Gilead Shares Fall After Company Misses On RevenueGilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biot
Gilead Shares Fall After Company Misses On Revenue
FOX Business / Posted 7 days ago
Gilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biotech company reported lower-than-expected first-quarter sales. Gilead said it earned an adjusted $4.3 billion, or $3.03 a share, in the quarter, compared with $4.6 billion,... Read more
13 related stories
7d
FOX Business
Gilead Shares Fall After Company Misses On RevenueGilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biot
Gilead Shares Fall After Company Misses On Revenue
FOX Business / Posted 7 days ago
Gilead Sciences Inc. shares fell 6% late Thursday after the Silicon Valley biotech company reported lower-than-expected first-quarter sales. Gilead said it earned an adjusted $4.3 billion, or $3.03 a share, in the quarter, compared with $4.6 billion,... Read more
7d
Chattanooga Times Free Press
Gilead 1Q profit tumbles on slower hepatitis C drug salesforecast of Wall Street analysts who were looking for earnings of $3.12 per sha
Gilead 1Q profit tumbles on slower hepatitis C drug sales
Chattanooga Times Free Press / Posted 7 days ago
forecast of Wall Street analysts who were looking for earnings of $3.12 per share, according to Zacks Investment research. Gilead Sciences Inc., based in Foster City, California, has grown into one of the world's biggest drugmakers thanks to its... Read more
13 related stories
7d
Market Watch
Gilead reports drop in Hepatitis C drug revenueGilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the f
Gilead reports drop in Hepatitis C drug revenue
Market Watch / Posted 7 days ago
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations. Shares in the company slid 5.3% in after-hours trading. The Foster City, Calif.,... Read more
13 related stories
7d
Daily Herald
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billionthe statement: • Viekira Pak sales of $414 million, estimate was $514 million.
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billion
Daily Herald / Posted 7 days ago
the statement: • Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.'s treatments • Imbruvica sales of $381 million; average estimate was $367 million •... Read more
32 related stories
7d
Chicago Tribune
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billionthe statement: --Viekira Pak sales of $414 million, estimate was $514 million.
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 billion
Chicago Tribune / Posted 7 days ago
the statement: --Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.'s treatments --Imbruvica sales of $381 million; average estimate was $367... Read more
32 related stories
7d
Crain's Chicago Business
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 Billionthe statement: Viekira Pak sales of $414 million, estimate was $514 million. T
AbbVie to acquire cancer drugmaker Stemcentrx for $5.8 Billion
Crain's Chicago Business / Posted 7 days ago
the statement: Viekira Pak sales of $414 million, estimate was $514 million. The hepatitis C therapy is competing with Gilead Sciences Inc. and Merck & Co.’s treatments Imbruvica sales of $381 million; average estimate was $367 million Net... Read more
32 related stories
9d
Roll Call
Aviation, Drug Pricing Keep Lobbyists Busy in Election Yearthe country's major pharmaceutical companies also spent more on K Street this q
Aviation, Drug Pricing Keep Lobbyists Busy in Election Year
Roll Call / Posted 9 days ago
the country's major pharmaceutical companies also spent more on K Street this quarter, including Pfizer Inc.; AbbVie Inc.; Gilead Sciences Inc.; AstraZeneca PLC; Novartis International AG; and Merck & Co. Inc. Together, those companies spent more... Read more
9d
TribLIVE
Dorfman: Looking at the cheapest stock in each sectorratio is six, and the stock fell 32 percent in the past year. The company is st
Dorfman: Looking at the cheapest stock in each sector
TribLIVE / Posted 9 days ago
ratio is six, and the stock fell 32 percent in the past year. The company is struggling under a heavy debt load. Gilead Sciences Inc. (GILD), a biotech firm from Foster City, Calif., repeats from last year as the cheapest stock in the... Read more
10d
The Globe and Mail
Calendar: What investors need to know for the week aheadHoldings Ltd.; First Quantum Minerals Ltd.; Ford Motor Co.; Genworth Financial
Calendar: What investors need to know for the week ahead
The Globe and Mail / Posted 10 days ago
Holdings Ltd.; First Quantum Minerals Ltd.; Ford Motor Co.; Genworth Financial Inc.; Genworth MI Canada Inc.; Gigamon Inc.; Gilead Sciences Inc.; GMP Capital Inc.; Groupon Inc.; HudBay Minerals Inc.; Interfor Corp.; Juniper Networks Inc.; LinkedIn... Read more
10d
Business Wire
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIVFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
Business Wire / Posted 10 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg;... Read more
13d
WBNS-10TV Columbus
AP National News Calendarfinancial results after the market closes. Amgen Inc. reports quarterly financ
AP National News Calendar
WBNS-10TV Columbus / Posted 13 days ago
financial results after the market closes. Amgen Inc. reports quarterly financial results after the market closes. Gilead Sciences Inc. reports quarterly financial results after the market closes. LinkedIn Corp. reports quarterly financial... Read more
14d
Business Wire
Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) anno
Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
Business Wire / Posted 14 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2016 financial results will be released on Thursday, April 28, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management... Read more
14d
Investopedia
3 Expensive All-Cap ETFs Worth Your While (KNOW, PDP)are performance-weighted, led by Apple Inc. (NASDAQ: AAPL) with 2.99%, The Pric
3 Expensive All-Cap ETFs Worth Your While (KNOW, PDP)
Investopedia / Posted 14 days ago
are performance-weighted, led by Apple Inc. (NASDAQ: AAPL) with 2.99%, The Priceline Group Inc. (NASDAQ: PCLN) at 2.83% and Gilead Sciences Inc. (NASDAQ: GILD) at 2.67%. The PowerShares DWA Momentum ETF has proven to be popular with investors,... Read more
16d
Boston Globe
Tufts Health Plan lifts restrictions on hepatitis C drugsprivate insurers negotiate significant, and undisclosed, discounts. A congress
Tufts Health Plan lifts restrictions on hepatitis C drugs
Boston Globe / Posted 16 days ago
private insurers negotiate significant, and undisclosed, discounts. A congressional investigation last year concluded that Gilead Sciences Inc., maker of Sovaldi and Harvoni, had priced the drugs for maximal profit, separate from the cost of... Read more
19 related stories
17d
Investopedia
Gilead to Provide Healthy Dose of Growth (GILD)Shares of biopharmaceutical company Gilead Sciences Inc. (GILD) rose 2.5% last
Gilead to Provide Healthy Dose of Growth (GILD)
Investopedia / Posted 17 days ago
Shares of biopharmaceutical company Gilead Sciences Inc. (GILD) rose 2.5% last week, reaching a four-month high of $98 thanks to positive comments from analysts at Barclays about not only the company's upcoming earnings report, but also its strength... Read more
17d
Newsmax
New Hep C Treatment Shows High Cure Ratesof patients than AbbVie's Viekira Pak, improving chances of making inroads into
New Hep C Treatment Shows High Cure Rates
Newsmax / Posted 17 days ago
of patients than AbbVie's Viekira Pak, improving chances of making inroads into the market domination currently enjoyed by Gilead Sciences Inc. Viekira Pak, which is approved for genotype 1, the most common form of the serious liver disease in the... Read more
17d
The Globe and Mail
These two stocks offer lessons in how not to go ‘the Valeant way’stunning rise and shocking fall. And there are two, in particular, that we migh
These two stocks offer lessons in how not to go ‘the Valeant way’
The Globe and Mail / Posted 17 days ago
stunning rise and shocking fall. And there are two, in particular, that we might suggest are very, very dissimilar. One, Gilead Sciences Inc., illustrates how a drug company can embrace research and development to build on its existing portfolio... Read more
19d
Business Wire
Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C TherapiesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) toda
Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
Business Wire / Posted 19 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating its two investigational, pangenotypic, fixed-dose combination therapies for the treatment of... Read more
19 related stories
19d
National Post
Story | Business Wire News Releases | News | Financial Post– Studies Highlight Progress with Approved Therapies and Investigational Pangen
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 19 days ago
– Studies Highlight Progress with Approved Therapies and Investigational Pangenotypic Regimens, Including Sofosbuvir/Velpatasvir (SOF/VEL) and SOF/VEL Plus GS-9857– FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today... Read more
19d
Business Wire
Gilead Presents New Data Highlighting Progress in Liver FibrosisFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today
Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Business Wire / Posted 19 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced data supporting the development of three investigational agents for the treatment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis... Read more
19d
National Post
Story | Business Wire News Releases | News | Financial PostGS-4997 and GS-9674, Investigational Compounds for the Treatment of NASH and PS
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 19 days ago
GS-4997 and GS-9674, Investigational Compounds for the Treatment of NASH and PSC – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced data supporting the development of three investigational agents for the... Read more
19d
Channel NewsAsia
New AbbVie hepatitis C regimen shows high cure rates: studiesof patients than AbbVie's Viekira Pak, improving chances of making inroads into
New AbbVie hepatitis C regimen shows high cure rates: studies
Channel NewsAsia / Posted 19 days ago
of patients than AbbVie's Viekira Pak, improving chances of making inroads into the market domination currently enjoyed by Gilead Sciences Inc. Viekira Pak, which is approved for genotype 1, the most common form of the serious liver disease in the... Read more
19 related stories
19d
WREG-TV Memphis
The most successful company founded the year you were bornit the biggest coffee chain in the world.1986 Celgene Corporation Market Cap:
The most successful company founded the year you were born
WREG-TV Memphis / Posted 19 days ago
it the biggest coffee chain in the world.1986 Celgene Corporation Market Cap: $77,556,800,000 Ticker Symbol: CELG Gilead Sciences Inc. Market Cap: $126,379,000,000 Ticker Symbol: GILD Founded by 29-year-old Michael L. Riordan, Gilead... Read more
4 related stories
20d
FOX 13 Utah
The most successful company founded the year you were bornit the biggest coffee chain in the world.1986 Celgene Corporation Market Cap:
The most successful company founded the year you were born
FOX 13 Utah / Posted 20 days ago
it the biggest coffee chain in the world.1986 Celgene Corporation Market Cap: $77,556,800,000 Ticker Symbol: CELG Gilead Sciences Inc. Market Cap: $126,379,000,000 Ticker Symbol: GILD Founded by 29-year-old Michael L. Riordan, Gilead... Read more
4 related stories
20d
FOX 6 Milwaukee
The most successful company founded the year you were bornit the biggest coffee chain in the world.1986 Celgene Corporation Market Cap:
The most successful company founded the year you were born
FOX 6 Milwaukee / Posted 20 days ago
it the biggest coffee chain in the world.1986 Celgene Corporation Market Cap: $77,556,800,000 Ticker Symbol: CELG Gilead Sciences Inc. Market Cap: $126,379,000,000 Ticker Symbol: GILD Founded by 29-year-old Michael L. Riordan, Gilead... Read more
4 related stories
20d
WTKR Norfolk
The most successful company founded the year you were bornit the biggest coffee chain in the world.1986 Celgene Corporation Market Cap:
The most successful company founded the year you were born
WTKR Norfolk / Posted 20 days ago
it the biggest coffee chain in the world.1986 Celgene Corporation Market Cap: $77,556,800,000 Ticker Symbol: CELG Gilead Sciences Inc. Market Cap: $126,379,000,000 Ticker Symbol: GILD Founded by 29-year-old Michael L. Riordan, Gilead... Read more
4 related stories
20d
CBS 6 Richmond
The most successful company founded the year you were bornit the biggest coffee chain in the world.1986 Celgene Corporation Market Cap:
The most successful company founded the year you were born
CBS 6 Richmond / Posted 20 days ago
it the biggest coffee chain in the world.1986 Celgene Corporation Market Cap: $77,556,800,000 Ticker Symbol: CELG Gilead Sciences Inc. Market Cap: $126,379,000,000 Ticker Symbol: GILD Founded by 29-year-old Michael L. Riordan, Gilead... Read more
4 related stories
20d
San Antonio Express-News
Gilead Sciences Inc. vs. Celgene Corporationnearly unlimited room to run for early in-the-know investors! To be one of them
Gilead Sciences Inc. vs. Celgene Corporation
San Antonio Express-News / Posted 20 days ago
nearly unlimited room to run for early in-the-know investors! To be one of them, just click here. The article Better Buy: originally appeared on Fool.com. Keith Speights owns shares of Celgene and... Read more
20d
National Post
Story | Business Wire News Releases | News | Financial PostFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Story | Business Wire News Releases | News | Financial Post
National Post / Posted 20 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed 48-week results from two large Phase 3 clinical trials (Studies 108 and 110) evaluating once-daily tenofovir alafenamide (TAF) 25 mg in... Read more
23d
TribLIVE
Dorfman: Alaska Air, Delta and NVR Make the 30-30 Clubtheir balance sheets seem somewhat stronger. Four biotech stocks are in the cl
Dorfman: Alaska Air, Delta and NVR Make the 30-30 Club
TribLIVE / Posted 23 days ago
their balance sheets seem somewhat stronger. Four biotech stocks are in the club: Abiomed Inc. (ABMD), Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Ligand Pharmaceuticals (LGND). My preference goes to Gilead, which has more than two dozen... Read more
26d
Boston Globe
For hepatitis C patients, no cure for high drug pricesdecided to price those drugs for maximal profit.” In January, Massachusetts At
For hepatitis C patients, no cure for high drug prices
Boston Globe / Posted 26 days ago
decided to price those drugs for maximal profit.” In January, Massachusetts Attorney General Maura Healey warned Gilead Sciences Inc. that its high prices for Sovaldi and Harvoni “may constitute an unfair trade practice in violation of... Read more
28d
Investopedia
Gilead's Price Target Raised at Jefferies (GILD)Shares of Gilead Sciences Inc. (GILD) climbed as much as 2.4% Wednesday, reachi
Gilead's Price Target Raised at Jefferies (GILD)
Investopedia / Posted 28 days ago
Shares of Gilead Sciences Inc. (GILD) climbed as much as 2.4% Wednesday, reaching a high of $97.50 after Jefferies analysts raised their 12-month price target to $101 from $97. Developing a Strong Growth Pipeline "We could see shares uptick on the... Read more
More

People in this news